The Swiss biopharmaceutical company, Actelion AG, will receive CHF 150 million (£66 million) up-front and up to CHF 3.15 billion in future milestone payments from GlaxoSmithKline as part of a co-development and co-commercialisation deal for Actelion’s treatment for primary insomnia, almorexant.
